☆ 4.6 Article

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

PLOS MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

Don Husereau et al.

Summary: The CHEERS 2022 statement is an updated version of reporting guidelines for health economic evaluations, providing guidance that can be more easily applied to all types of evaluations. It emphasizes stakeholder involvement and is broadly applicable to interventions aimed at improving individual or population health.

CLINICAL THERAPEUTICS (2022)

Add to Collection

Article Immunology

Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis

Mark M. Janko et al.

Summary: This study estimated the incremental cost-effectiveness ratios (ICERs) of rotavirus vaccination in 195 countries using meta-regression methods and location-specific vaccine efficacy estimates. The results showed that vaccine efficacy, cost, GDP, and rotavirus disability-adjusted life-years (DALYs) were important factors in determining the variability of ICERs. The findings support the expansion of rotavirus vaccination programs, particularly in countries eligible for support from Gavi, The Vaccine Alliance.

VACCINE (2022)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial

Mark F. Cotton et al.

Summary: This study compared the safety and immunogenicity of VPM1002 and BCG in HIV exposed and unexposed newborn babies, showing that VPM1002 was less reactogenic than BCG, with differences in immunogenic responses.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Economics

Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018

Mark Jit

Summary: This study aimed to investigate the consistency of country-level decisions about HPV vaccine introduction with cost-effectiveness threshold. A cost-effectiveness threshold of 60% to 65% of GDP per capita has the best ability to discriminate countries that introduced vaccination, with a diagnostic odds ratio of about 7. For low-income countries, the optimal threshold was lower, at 30% to 40% of GDP per capita.

VALUE IN HEALTH (2021)

Add to Collection

Article Multidisciplinary Sciences

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Han Fu et al.

Summary: Research suggests that a future TB vaccine could have a significant impact on global rifampicin-resistant TB burden, particularly in countries like India, China, Indonesia, Pakistan, and the Russian Federation. When combined with improvements in diagnosis and treatment of drug-resistant TB, the implementation of the vaccine may prove to be effective.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China

Chathika K. Weerasuriya et al.

Summary: The study found that novel TB vaccines could greatly reduce the burden of RR/MDR-TB in the future, while also averting the need for second-line therapy. The cost-effectiveness of vaccination may vary depending on the characteristics of the vaccine and the setting.

BMC MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Cost-effectiveness of HPV vaccination in 195 countries: A meta-regression analysis

Katherine L. Rosettie et al.

Summary: Researchers conducted a meta-regression analysis to predict the incremental cost-effectiveness ratios (ICERs) of HPV vaccination in 195 countries, showing a global mean predicted ICER of US$4,217 per DALY averted. The study found that ICERs are positively related to vaccine cost, and negatively related to cervical cancer burden. Predictions suggest that HPV vaccination is most cost-effective in Sub-Saharan Africa and South Asia, with the lowest ICERs in those regions.

PLOS ONE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis

Sachin Silva et al.

Summary: Failure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses, with the continuing decline in tuberculosis mortality rates driving global economic losses, and COVID-19 disruptions further adding to this cost.

LANCET GLOBAL HEALTH (2021)

Add to Collection

Editorial Material Respiratory System

The case for assessing the full value of new tuberculosis vaccines

Nebiat Gebreselassie et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection

Article Economics

Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates

Allison Portnoy et al.

PHARMACOECONOMICS (2020)

Add to Collection

Review Infectious Diseases

Cost of tuberculosis treatment in low- and middle-income countries: systematic review and meta-regression

M. Siapka et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2020)

Add to Collection

Article Cell Biology

Potential impact of tuberculosis vaccines in China, South Africa, and India

Rebecca C. Harris et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

D. R. Tait et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Health Care Sciences & Services

Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia

Tharani Loganathan et al.

HEALTH POLICY AND PLANNING (2018)

Add to Collection

Article Economics

Cost-Effectiveness Thresholds: the Past, the Present and the Future

Praveen Thokala et al.

PHARMACOECONOMICS (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data

Jessica Ochalek et al.

BMJ GLOBAL HEALTH (2018)

Add to Collection

Article Infectious Diseases

The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan

Susan van den Hof et al.

BMC INFECTIOUS DISEASES (2016)

Add to Collection

Article Economics

County-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

Beth Woods et al.

VALUE IN HEALTH (2016)

Add to Collection

Review Economics

Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review

Yoko V. Laurence et al.

PHARMACOECONOMICS (2015)

Add to Collection

Article Public, Environmental & Occupational Health

Disability weights for the Global Burden of Disease 2013 study

Joshua A. Salomon et al.

LANCET GLOBAL HEALTH (2015)

Add to Collection

Article Multidisciplinary Sciences

Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries

Gwenan M. Knight et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Add to Collection

Article Economics

Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6

Andrew H. Briggs et al.

VALUE IN HEALTH (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.